Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v8-EN | Version v5-FR | |
|---|---|---|
| Language | English | French |
| Date Updated | 2023-02-14 | 2023-02-06 |
| Drug Identification Number | 00828602 | 00828602 |
| Brand name | 0.4% LIDOCAINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION | 0.4% LIDOCAINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION |
| Common or Proper name | 0.4% LIDOCAINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION | 0.4% LIDOCAINE HYDROCHLORIDE AND 5% DEXTROSE INJECTION |
| Company Name | BAXTER CORPORATION | BAXTER CORPORATION |
| Ingredients | DEXTROSE LIDOCAINE HYDROCHLORIDE | DEXTROSE LIDOCAINE HYDROCHLORIDE |
| Strength(s) | 50MG 4MG | 50MG 4MG |
| Dosage form(s) | SOLUTION SOLUTION | SOLUTION SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging size | 500mL bag | 500mL bag |
| ATC code | C01BB | C01BB |
| ATC description | ANTIARRHYTHMICS, CLASS I AND III | ANTIARRHYTHMICS, CLASS I AND III |
| Reason for shortage | Demand increase for the drug. | Demand increase for the drug. |
| Anticipated start date | 2023-01-09 | 2023-01-09 |
| Actual start date | 2023-01-09 | 2023-01-09 |
| Estimated end date | 2023-02-13 | 2023-02-13 |
| Actual end date | 2023-02-13 | |
| Shortage status | Resolved | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | Baxter product LIDOCAINE HYDROCHLORIDE 0.4% AND 5% DEXTROSE INJECTION (250 mL bags) is available as a substitute. | Baxter product LIDOCAINE HYDROCHLORIDE 0.4% AND 5% DEXTROSE INJECTION (250 mL bags) is available as a substitute. |
| Health Canada comments |